Skip to main content
Premium Trial:

Request an Annual Quote

Second Chance for 23andMe

The FDA should back off of 23andMe and allow the firm to continue selling its consumer genomics service because it is unlikely to lead to unnecessary diagnostic tests and medical procedures, argues Forbes writer Frida Polli.

Polli takes issue with FDA's recent move to make 23andMe cease marketing its health-related genomics services, saying that the concern that people will go directly from receiving specific genetic information and to rush to expensive and unnecessary tests or procedures is overrated.

"Many steps exist between a woman learning through 23andMe that she has a mutation in one of the BRCA genes linked to breast cancer, and her undergoing a double mastectomy," she writes. "While the 23andMe kit comes in the mail and the results in an email, surgery is hardly undergone with the same ease."

Further, early detection was a main reason for creating the company, Polli says, noting that early detection and prevention may offer savings for the healthcare system.

Polli echoes the sentiments of others, including Misha Angrist, who have argued against FDA's intervention, which some view as overly paternalistic and stifling to new industry.

The big question FDA posed to 23andMe that Polli does not address, however, is whether the test works. If the company is claiming that the genetic information it provides is for use in health, rather than for curiosity or ancestry information, FDA has said it wants to know if the test is valid.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.